| D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia (NCT00237809) | Yale University | 2002-09-01 |
| Broad Effectiveness: Study With Aripiprazole (NCT00036361) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2002-07-01 |
| RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice (NCT00458367) | Janssen Pharmaceutica N.V., Belgium | 2002-06-01 |
| Families Coping With Mental Illness Program (NCT00435721) | North Suffolk Mental Health Association | 2002-06-01 |
| Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia (NCT00176423) | University of Maryland, Baltimore | 2002-05-01 |
| Tetrabenazine for Partial Responders (NCT00362804) | Centre for Addiction and Mental Health | 2002-02-01 |
| Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP) (NCT00119574) | US Department of Veterans Affairs | 2002-01-01 |
| Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients (NCT00159770) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2001-11-01 |
| Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients (NCT00515489) | Janssen-Cilag, S.A. | 2001-11-01 |
| Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features (NCT00202293) | Melbourne Health | 2001-10-01 |
| A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. (NCT00495118) | Janssen, LP | 2001-10-01 |
| Generalization of Training in Schizophrenia (NCT00108199) | US Department of Veterans Affairs | 2001-10-01 |
| Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People (NCT00169052) | Dartmouth-Hitchcock Medical Center | 2001-09-01 |
| Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia (NCT00034801) | Eli Lilly and Company | 2001-09-01 |
| Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants (NCT00419146) | University Hospital, Aker | 2001-09-01 |
| Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia (NCT00320723) | North Suffolk Mental Health Association | 2001-07-01 |
| Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia (NCT00511628) | Janssen-Cilag, S.A. | 2001-07-01 |
| Clinical Trial of Dipyridamole in Schizophrenia (NCT00349973) | University of Maryland, Baltimore | 2001-05-01 |
| A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine. (NCT00378183) | Janssen, LP | 2001-02-01 |
| Clinical Estradiol Trial in Women With Schizophrenia (NCT00206570) | Bayside Health | 2001-01-01 |
| Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia (NCT00430560) | VA Office of Research and Development | 2000-10-01 |
| Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual (NCT00498550) | Dartmouth-Hitchcock Medical Center | 2000-10-01 |
| Cognitive - Behavioral Therapy (NCT00018629) | US Department of Veterans Affairs | 2000-05-01 |
| Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia (NCT00469664) | Research Foundation for Mental Hygiene, Inc. | 2000-02-01 |
| Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder (NCT00179062) | Vanderbilt University | 2000-02-01 |
| A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder. (NCT00558298) | Janssen, LP | 2000-02-01 |
| Adjunctive Treatment for Decreasing Symptoms of Schizophrenia (NCT00222235) | University of Maryland, Baltimore | 2000-01-01 |
| Alcoholism and Schizophrenia: Effects of Clozapine (NCT00169026) | Dartmouth-Hitchcock Medical Center | 1999-05-01 |
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap (NCT02640300) | Centre for Addiction and Mental Health | 1999-05-01 |
| Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors (NCT00178932) | Northwestern University | 1998-11-01 |
| To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia (NCT00007774) | US Department of Veterans Affairs | 1998-03-01 |
| Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis (NCT00157313) | Bispebjerg Hospital | 1998-01-01 |
| Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder (NCT00018642) | US Department of Veterans Affairs | 1997-04-01 |
| A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder (NCT00253110) | Janssen, LP | 1996-05-01 |
| Genetic Study of Schizophrenia (NCT00001486) | National Institute of Mental Health (NIMH) | 1995-07-15 |
| Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia (NCT00001198) | National Institute of Mental Health (NIMH) | 1984-03-19 |
| Pharmacokinetic Characterization of Intramuscular Olanzapine Depot (NCT00094640) | Eli Lilly and Company | |
| Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients (NCT00534898) | Beersheva Mental Health Center | |
| A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder (NCT00297388) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |